Methylated KCNQ5 was positive in 36.6% (37/101) of SP, 75.0% (15/20) of AA, 60.0% (3/5) of stage 0 CRC, 84.4% (27/32) of stage I CRC, 82.8% (48/58) of stage II CRC, 69.5% (41/59) of stage III CRC, 66.7% (14/21) of stage IV CRC, and 87.0% (20/23) of CRC of unknown stage. This evidence concerns the gene KCNQ5 and colorectal carcinoma.